The effectiveness of Ondansetron in acute kidney injury in patients admitted to the ICU

Determining the effectiveness of Ondansetron in acute kidney injury in patients admitted to the ICU

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190325043107N54

Enrollment

100

Registered

2025-02-14

Start date

2025-02-16

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal function status. Disorders resulting from impaired renal tubular function

Interventions

Intervention 1: Intervention group: In the intervention group, 8 mg daily (equivalent to 4 cc) of ondansetron from Caspian Tamin Pharmaceutical Company will slowly be injected intravenously within 5 m

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 years and above Intensive care unit admission for more than 72 hours

Exclusion criteria

Exclusion criteria: Patients with known underlying kidney disease All patients with creatinine levels >1.5 mg/dL on admission Patients with any type of headache, including migraine Patients taking QT prolonging medications

Design outcomes

Primary

Measure	Time frame
Renal function. Timepoint: Every six hours for 4 days. Method of measurement: Measurement of urine and serum creatinine levels.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Khanbabayi Gol

Tabriz University of Medical Sciences

Khanbabayimehdi69@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026